



UPDATE --TRACON Pharmaceuticals to Present at the JMP Securities Life Science Conference

San Diego, CA – June 18, 2015 -- In a release issued yesterday by TRACON Pharmaceuticals (TCON), the date and time of the conference have been updated to 3:30 pm EDT on Tuesday, June 23, 2015.

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the JMP Securities Life Science Conference at 3:30 pm EDT on Tuesday, June 23, 2015, at the St. Regis Hotel in New York, NY.

To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

About TRACON

TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON’s current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Contact:

Casey Logan

Chief Business Officer

(858) 550-0780 ext. 236

clogan@traconpharma.com